Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.44 |
| ▸ | SELL | P14151 | 1/20 | 0.44 |
| ▸ | SELP | P16109 | 1/20 | 0.44 |
| ▸ | DNM2 | P50570 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25434571 | 0.83 | SELL (0.47) | ALOX5HDAC1HDAC2HDAC3SELL | |
| SCHEMBL9313474 | 0.78 | SELL (0.58) | ALOX5HDAC1HDAC6SELLSELP | |
| SCHEMBL11618503 | 0.73 | KMT2A (0.56) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL11115291 | 0.72 | ALDH1A1 (0.56) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL24871622 | 0.72 | ALOX5 (0.57) | ALOX5SELLSELPDNM2 | |
| SCHEMBL9143670 | 0.72 | NAAA (0.68) | ALOX5 | |
| SCHEMBL31099240 | 0.72 | SELL (0.55) | ALOX5HDAC1SELLSELP | |
| SCHEMBL13952095 | 0.71 | ALOX5 (0.82) | ALOX5DNM2 | |
| SCHEMBL368400 | 0.71 | HDAC1 (0.53) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6385721 | 0.70 | HDAC6 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197383-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | UNIV CALIFORNIA (US) | 2025-06-19 | — | — | US | disclosed |
| EP-4486738-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023168240-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168240-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197383-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | ENPP1, ENPP2, ENPP3 | ALOX5 1100/4885HDAC1 2743/4885HDAC2 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.